NT5E and neoplasm: In human EGFRm tumours, targeting CD73 shows promising results, as demonstrated by ongoing clinical trials testing adenosine pathway inhibitors, either as monotherapy or in combination with ICIs and/or TKIs [56,61,63,75,76].